10074-G5
- N-2-联苯基-7-硝基-2,1,3-苯并恶二唑-4-胺
货号: abs813455
货号-规格 | 货期 | 价格 | 数量 |
abs813455-5mg | 1-2周 | ¥679.00 | - + |
abs813455-10mg | 1-2周 | ¥938.00 | - + |
abs813455-25mg | 1-2周 | ¥1504.00 | - + |
abs813455-50mg | 1-2周 | ¥2535.00 | - + |

产品描述 | |
描述 | 10074-G5 is an inhibitor of c-Myc-Max dimerization (IC50 =146 μM) that operates by binding and stabilizing c-Myc in its monomeric form. 10074-G5 inhibits c-Myc/Max heterodimer formation and its transcriptional activity. 10074-G5 is most efficient in inducing neuronal differentiation and lipid accumulation in MYCN-amplified neuroblastoma cells. |
纯度 | >97% |
储存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
基本信息 | |
别名 | N-2-联苯基-7-硝基-2,1,3-苯并恶二唑-4-胺 |
外观 | red powder |
可溶性/溶解性 | Ethanol :10 mg/mL (30.09 mM) DMSO :56 mg/mL (168.5 mM) |
生物活性 | |
靶点 | c-Myc |
In vitro(体外研究) | 10074-G5 binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. In vitro, 10074-G5 inhibits the growth of Daudi Burkitt's lymphoma cells and disrupts c-Myc/Max dimerization. Daudi cells accumulates 10074-G5, and the highest intracellular concentration is observed at 6 h. 10074-G5 inhibits c-Myc/Max dimerization in Daudi cells by approximately 75% at 4 h, and this inhibition is maintained through 24 h of incubation. Total c-Myc protein expression also decreases, and after 24 h exposure to 10 μM 10074-G5, c-Myc protein expression decreases approximately 40% compared with vehicle-treated control. 10074-G5 is cytotoxic in vitro against Daudi and HL-60 cells, which overexpress c-Myc . |
In vivo(体内研究) | The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. is 37 min, and peak plasma concentration is 58 μM, which is 10-fold higher than peak tumor concentration. The lack of antitumor activity probably is caused by the rapid metabolism of 10074-G5 to inactive metabolites, resulting in tumor concentrations of 10074-G5 insufficient to inhibit c-Myc/Max dimerization. Plasma 10074-G5 peak concentration (Cmax) of 58.5 ± 2.7 nmol/ml is observed at 5 min after intravenous administration of 20 mg/kg to mice bearing Daudi xenografts, 10074-G5 concentration in plasma declines rapidly. Except for lung, liver, and fat, tissue concentrations of 10074-G5 are lower than those of plasma at all time points. |
参考文献 | |
参考文献 |